SELP: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of SELP. The page also collects GeneMedi's different modalities and formats products for SELP in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the SELP target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
This gene encodes a 140 kDa protein that is stored in the alpha-granules of platelets and Weibel-Palade bodies of endothelial cells. This protein redistributes to the plasma membrane during platelet activation and degranulation and mediates the interaction of activated endothelial cells or platelets with leukocytes. The membrane protein is a calcium-dependent receptor that binds to sialylated forms of Lewis blood group carbohydrate antigens on neutrophils and monocytes. Alternative splice variants may occur but are not well documented. [provided by RefSeq, Jul 2008]
|Gene Official Name||SELP|
|Gene Alias||CD62, CD62P, GMP140, GRMP, LECAM3, PADGEM, PSEL|
|Protein Sub-location||Transmembrane Protein|
|Category||Therapeutics Target, INN Index|
Pre-made SELP-specific INN-index biosimilar (antibody&conjugates)-Crizanlizumab, Inclacumab, torapsel
Anti-SELP therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
|Cat No.||Products Name (INN Index)||INN Name||Previous Name||Target||Format||Order|
|GMP-Bios-ab-123||Pre-Made Crizanlizumab biosimilar, Whole mAb, Anti-SELP Antibody: Anti-CD62/CD62P/GMP140/GRMP/LECAM3/PADGEM/PSEL therapeutic antibody||Crizanlizumab||SELP||Whole mAb|
|GMP-Bios-ab-270||Pre-Made Inclacumab biosimilar, Whole mAb, Anti-SELP Antibody: Anti-CD62/CD62P/GMP140/GRMP/LECAM3/PADGEM/PSEL therapeutic antibody||Inclacumab||SELP||Whole mAb|
|GMP-Bios-INN-1027||Pre-Made Torapsel Biosimilar, Fusion Protein targeting SELP fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting CD62/CD62P/GMP140/GRMP/LECAM3/PADGEM/PSEL||torapsel||SELP||Fusion Protein|
Pre-made anti-SELP inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-SELP benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-SELP mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
|Cat No.||Antibody Name||Format||Classified by tag||Order|
|GM-Tg-hg-T10965-Ab||Anti-SELP monoclonal antibody||mab||Biofunctional antibody, Therapeutics Target antibody|